<DOC>
	<DOCNO>NCT01221259</DOCNO>
	<brief_summary>This study design single ascend dose study healthy subject evaluate safety , tolerability , Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) plasma Cerebrospinal ( CSF ) follow single oral dos E2212 .</brief_summary>
	<brief_title>A Randomized , Double-blind , Placebo-controlled , Sequential Ascending , Single-dose Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics E2212 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Healthy men woman nonchild bear potential age 18 55 year old time Screening ; 2 . Body mass index ( BMI ) 18 30 kg/m2 Screening ; 3 . Are willing able comply aspect protocol ; 4 . Provide write informed consent . 1 . Clinically important abnormality physical examination , vital sign clinical laboratory . 2 . History serious medical illness 3 . Smoking use tobaccocontaining product within past 3 month 4 . History alcohol drug abuse within past 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>